John Perry

Assistant Professor

Beckman Research Institute, City of Hope

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

John Perry is an Assistant Professor at the City of Hope Beckman Research Institute in the United States. His research focuses on cancer therapy, specifically targeting homologous recombination-deficient cancers, mitochondrial dynamics in leukemic stem cells, and transcription-replication conflicts. Recent works include the discovery of small molecule inhibitors and peptide therapeutic approaches aimed at improving cancer treatment outcomes.

Articles (10)

Year:

2025

Year:

2024

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

Carlo Baggio

University of California, Riverside

UNITED STATES

View details

Adam Bailis

Professor of Health Science and Associate Dean of Research

Thomas Jefferson University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

John Perry

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Discovery and Characterization of Small Molecule Inhibitors Targeting Exonuclease 1 for Homologous Recombination-Deficient Cancer Therapy

AOH1996 targets mitochondrial dynamics and metabolism in leukemic stem cells via mitochondrial PCNA inhibition.

Small molecule targeting of transcription-replication conflict for selective chemotherapy.

Design, Synthesis, and Structural Characterization of Lysine Covalent BH3 Peptides Targeting Mcl-1

Product inhibition kinetics determinations - Substrate interaction affinity and enzymatic kinetics using one quantitative FRET assay.

Novel Peptide Therapeutic Approaches for Cancer Treatment.

Isopeptidase Kinetics Determination by a Real Time and Sensitive qFRET Approach.

Variants of the human <i>RAD52</i> gene confer defects in ionizing radiation resistance and homologous recombination repair in budding yeast.

Human ARMT1 structure and substrate specificity indicates that it is a DUF89 family damage-control phosphatase.

N-locking stabilization of covalent helical peptides: Application to Bfl-1 antagonists.

Collaborators (2)

Carlo Baggio

Adam Bailis

Make your next move.